StockData
OMERNasdaqPharmaceutical PreparationsFiscal year ends December 31

OMEROS CORP

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$16.35+0.15 (+0.93%)

Close on Oct 19, 2026

Market cap
$1.47B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 12, 2026, during market hours (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 12, 2026During market hours$28.50M–$0.02
Q1 FY2026
Ended Mar 31, 2026
May 13, 2026During market hours$9.89M$0.62$-0.24
Q4 FY2025
Ended Dec 31, 2025
Mar 31, 2026During market hours–$0.98$3.14
Q3 FY2025
Ended Sep 30, 2025
Nov 13, 2025During market hours–$-0.47$-0.34
Q2 FY2025
Ended Jun 30, 2025
Aug 14, 2025During market hours–$-0.43–
Q1 FY2025
Ended Mar 31, 2025
May 15, 2025During market hours–$-0.58–
Q4 FY2024
Ended Dec 31, 2024
Mar 31, 2025During market hours–$-0.54–
Q3 FY2024
Ended Sep 30, 2024
Nov 13, 2024During market hours–$-0.56–
Q2 FY2024
Ended Jun 30, 2024
Aug 7, 2024During market hours–$-0.97–
Q1 FY2024
Ended Mar 31, 2024
Apr 1, 2024During market hours–$-0.15–
Q3 FY2023
Ended Sep 30, 2023
Nov 9, 2023During market hours–$-0.60–

Press releases

Announcements Omeros filed with the SEC